Cell and Gene Therapy (CGT) Access Model Implementation and Monitoring Support Contract
The Cell and Gene Therapy Access Model has the potential to make groundbreaking treatments more widely available to those who need them and reduce long-term healthcare costs.
- Timothy Hill, AIR Senior Vice President, Health
Cell and gene therapies (CGTs) are a growing class of transformative, one-time medicines that use genetic material or living cells to treat various rare and severe diseases at a molecular or cellular level. The cost of these therapies can reach millions of dollars, often making them inaccessible to the populations of greatest need for treatment. The Centers for Medicare & Medicaid Services (CMS) CGT Access Model aims to make CGTs more accessible to Medicaid recipients, ultimately improving health outcomes, reducing health care costs, and fostering health equity.
The CGT Access Model, which will test a CMS- and state-led approach to negotiating and administering outcomes-based agreements, will focus on Sickle Cell Disease (SCD). SCD is a genetic blood disorder that disproportionately affects Black and Hispanic populations, often causing episodes of excruciating pain, hospitalizations, and a decreased average life expectancy that is 20 years shorter than the average life expectancy in the U.S.
AIR will serve a pivotal role by monitoring the implementation and outcomes of the CGT Access Model and conducting comprehensive environmental scans and data analysis.
